Cargando…
ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
BACKGROUND: The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. METHODS: In each of two laboratory studies, 20 d...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660952/ https://www.ncbi.nlm.nih.gov/pubmed/31349867 http://dx.doi.org/10.1186/s13071-019-3632-3 |
_version_ | 1783439389692526592 |
---|---|
author | McTier, Tom L. Kryda, Kristina Wachowski, Martha Mahabir, Sean Ramsey, Deborah Rugg, Doug Mazaleski, Mark Therrien, Carol Adams, Eric Wolff, T. Bowman, Dwight D. |
author_facet | McTier, Tom L. Kryda, Kristina Wachowski, Martha Mahabir, Sean Ramsey, Deborah Rugg, Doug Mazaleski, Mark Therrien, Carol Adams, Eric Wolff, T. Bowman, Dwight D. |
author_sort | McTier, Tom L. |
collection | PubMed |
description | BACKGROUND: The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. METHODS: In each of two laboratory studies, 20 dogs ≥ 12 months of age were randomly allocated to receive a subcutaneous injection of saline or PH 12 on Day 0 and were then inoculated with 50 D. immitis third-stage larvae (L(3)) on Day 365. All dogs were necropsied ~ 5 months post-inoculation for adult worm counts. The field efficacy study included dogs ≥ 10 months of age from 19 veterinary clinics in the USA treated with either 20 monthly doses of Heartgard® Plus (HG Plus) (296 dogs) or two doses of PH 12 (297 dogs) on Days 0 and 365. Efficacy was determined on Days 365, 480 and 605 using adult HW antigen and microfilaria testing to assess adult HW infection. RESULTS: PH 12 was 100% effective in preventing HW disease in all three of these studies. In the laboratory studies, no PH 12-treated dogs had any adult HWs, whereas all control dogs in both studies had adult HWs [geometric mean, 30.2 (range, 22–37) for Study 1 and 32.6 (22–44) for Study 2]. In the field study, all dogs treated with PH 12 tested negative for adult HW infection on all test days (Days, 365, 480 and 605), whereas four dogs receiving HG Plus (positive control) tested positive for HWs during the study (three dogs on Day 365 and one dog on Day 480). All four dogs treated with HG Plus that subsequently tested positive for HWs during the field study were from the lower Mississippi River Valley region, where HW resistance to macrocyclic lactone preventives has been confirmed to occur. PH 12 was significantly better than HG Plus in preventing heartworm disease in the field study (P = 0.0367). PH 12 was well-tolerated in both laboratory and field studies. CONCLUSIONS: A single dose of ProHeart® 12 was 100% effective in preventing heartworm disease in dogs for a full year in both laboratory and field studies. |
format | Online Article Text |
id | pubmed-6660952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66609522019-08-01 ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months McTier, Tom L. Kryda, Kristina Wachowski, Martha Mahabir, Sean Ramsey, Deborah Rugg, Doug Mazaleski, Mark Therrien, Carol Adams, Eric Wolff, T. Bowman, Dwight D. Parasit Vectors Research BACKGROUND: The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. METHODS: In each of two laboratory studies, 20 dogs ≥ 12 months of age were randomly allocated to receive a subcutaneous injection of saline or PH 12 on Day 0 and were then inoculated with 50 D. immitis third-stage larvae (L(3)) on Day 365. All dogs were necropsied ~ 5 months post-inoculation for adult worm counts. The field efficacy study included dogs ≥ 10 months of age from 19 veterinary clinics in the USA treated with either 20 monthly doses of Heartgard® Plus (HG Plus) (296 dogs) or two doses of PH 12 (297 dogs) on Days 0 and 365. Efficacy was determined on Days 365, 480 and 605 using adult HW antigen and microfilaria testing to assess adult HW infection. RESULTS: PH 12 was 100% effective in preventing HW disease in all three of these studies. In the laboratory studies, no PH 12-treated dogs had any adult HWs, whereas all control dogs in both studies had adult HWs [geometric mean, 30.2 (range, 22–37) for Study 1 and 32.6 (22–44) for Study 2]. In the field study, all dogs treated with PH 12 tested negative for adult HW infection on all test days (Days, 365, 480 and 605), whereas four dogs receiving HG Plus (positive control) tested positive for HWs during the study (three dogs on Day 365 and one dog on Day 480). All four dogs treated with HG Plus that subsequently tested positive for HWs during the field study were from the lower Mississippi River Valley region, where HW resistance to macrocyclic lactone preventives has been confirmed to occur. PH 12 was significantly better than HG Plus in preventing heartworm disease in the field study (P = 0.0367). PH 12 was well-tolerated in both laboratory and field studies. CONCLUSIONS: A single dose of ProHeart® 12 was 100% effective in preventing heartworm disease in dogs for a full year in both laboratory and field studies. BioMed Central 2019-07-26 /pmc/articles/PMC6660952/ /pubmed/31349867 http://dx.doi.org/10.1186/s13071-019-3632-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research McTier, Tom L. Kryda, Kristina Wachowski, Martha Mahabir, Sean Ramsey, Deborah Rugg, Doug Mazaleski, Mark Therrien, Carol Adams, Eric Wolff, T. Bowman, Dwight D. ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months |
title | ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months |
title_full | ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months |
title_fullStr | ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months |
title_full_unstemmed | ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months |
title_short | ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months |
title_sort | proheart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (dirofilaria immitis) disease in dogs in the usa for 12 months |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660952/ https://www.ncbi.nlm.nih.gov/pubmed/31349867 http://dx.doi.org/10.1186/s13071-019-3632-3 |
work_keys_str_mv | AT mctiertoml proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT krydakristina proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT wachowskimartha proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT mahabirsean proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT ramseydeborah proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT ruggdoug proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT mazaleskimark proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT therriencarol proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT adamseric proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT wolfft proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months AT bowmandwightd proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months |